비타민 B12 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of vitamin B12 Market

The global vitamin B12 market is poised for significant growth over the next decade. Valued at USD 216.8 million in 2025, the market is projected to rise to USD 230 million in 2026 and reach USD 406 million by 2034, reflecting a robust CAGR of 7.4% from 2026 to 2034. The market's growth is fueled by increasing awareness of health and wellness, rising prevalence of vitamin B12 deficiencies, and the popularity of plant-based diets that necessitate supplementation.

Vitamin B12, also known as cobalamin, is a water-soluble vitamin critical for DNA synthesis, red blood cell formation, fatty acid metabolism, and neurological health. Its deficiency can lead to anemia, neurological symptoms, and impaired metabolism of homocysteine and methanoic acid. Animal-derived foods such as milk, meat, eggs, and fish are natural sources of vitamin B12, making vegetarians and vegans particularly susceptible to deficiencies, further driving demand for supplements and fortified products.

Market Drivers and Growth Factors

The market growth is primarily driven by the rising prevalence of vitamin B12 deficiency and neurological conditions worldwide. The trend toward preventive healthcare and increasing health awareness has led to a surge in demand for supplements and fortified foods. For instance, Quadram Institute and the University of Kent in December 2023 developed new sustainable technology for large-scale cobalamin production with reduced use of cyanide and cobalt, enhancing product safety and supply efficiency.

Product innovations also contribute to market expansion. In June 2023, Procter & Gamble's brand VOOST launched pomegranate citrus-flavored vitamin B12 gummies aimed at supporting cellular energy and metabolism, reflecting growing consumer preference for palatable supplement forms. Furthermore, the COVID-19 pandemic boosted demand for immune-supportive vitamins, including B12, as consumers sought nutritional interventions, although the market saw a slight correction in 2022-2023 due to prior stockpiling of APIs.

Market Segmentation

By type, cyanocobalamin dominated the market with 60.22% share in 2026 due to its stability, availability, and cost-effectiveness. It is widely used in pharmaceutical formulations and fortified foods. Methylcobalamin followed as the second-largest segment, appreciated for higher bioavailability and neurological benefits. Adenosylcobalamin and hydroxocobalamin hold smaller market shares but are gaining traction due to advancements in production technologies.

By application, the food grade segment led with an 81.83% share in 2026, driven by increased consumption of fortified foods and functional beverages. The pharmaceutical grade segment is expected to grow steadily due to rising prevalence of peripheral neuropathy, macular degeneration, and atrophic gastritis, necessitating cobalamin supplementation.

By end-user, the food & nutraceuticals industry dominated with a 59.65% share in 2026, fueled by demand for nutrition-rich products like dairy substitutes, energy bars, and fortified beverages. The pharmaceutical industry is growing as well, particularly in regions with high B12 deficiency rates among elderly populations, such as the U.S., where 6-20% of adults over 60 are affected.

Regional Insights

Asia Pacific led the market in 2025 with a revenue of USD 126.6 million, driven by high prevalence of diabetic neuropathy, increasing geriatric population, and growing awareness of dietary supplements in China, India, and Southeast Asia. China, as the largest producer and consumer of cyanocobalamin, accounts for nearly 90% of global production.

Europe is witnessing rapid growth due to innovation in nutrition and wellness sectors, regulatory support, and rising prevalence of pernicious anemia. Germany and the UK markets are projected to reach USD 8.4 million and USD 3 million, respectively, by 2026. North America's market, led by the U.S., is expected to reach USD 46.8 million in 2026, supported by preventive healthcare awareness and growing neurological conditions. The rest of the world sees gradual growth driven by awareness campaigns and efforts to combat micronutrient malnutrition.

Key Industry Players and Developments

Leading companies include EUROAPI (France), CSPC Pharmaceutical Holdings Co., Ltd. (China), Ningxia Kingvit Pharmaceutical (China), Pharmavit (Netherlands), and NCPC International Corp. (China). Notable developments include EUROAPI's USD 25 million biomass boiler investment in France (August 2023) to expand B12 production capacity and Lupin Limited's Cyanocobalamin Nasal Spray launch (February 2024) in the U.S. to address pernicious anemia.

Conclusion

The global vitamin B12 market is set for steady growth between 2025 and 2034. Rising health awareness, an aging population, growing prevalence of B12 deficiencies, and strategic product launches in pharmaceuticals and fortified foods are key growth drivers. While high dependency on China for supply and production costs may restrain growth, innovations in production technologies and bioavailable formulations are likely to sustain market expansion. With Asia Pacific at the forefront and Europe and North America showing promising growth, the global B12 market is evolving into a competitive and opportunity-rich industry.

Segmentation By Type

• Cyanocobalamin
• Methylcobalamin
• Adenosylcobalamin
• Hydroxocobalamin

By Application

• Food Grade
• Pharmaceutical Grade
• Feed Grade

By End-user

• Pharmaceutical Industry
• Food & Nutraceuticals Industry
• Others

By Region

• North America (By Type, By Application, By End-user, By Country)
  • U.S.
  • Canada
• Europe (By Type, By Application, By End-user, By Country)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, By Application, By End-user, By Country)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Type, By Application, By End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview Regulatory Scenario, By Key Regions
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. Impact of COVID-19 on the Market

5. Global Vitamin B12 Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Cyanocobalamin
  • 5.1.2. Methylcobalamin
  • 5.1.3. Adenosylcobalamin
  • 5.1.4. Hydroxocobalamin
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Food Grade
  • 5.2.2. Pharmaceutical Grade
  • 5.2.3. Feed Grade
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Pharmaceutical Industry
  • 5.3.2. Food & Nutraceuticals Industry
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Vitamin B12 Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Cyanocobalamin
  • 6.1.2. Methylcobalamin
  • 6.1.3. Adenosylcobalamin
  • 6.1.4. Hydroxocobalamin
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Food Grade
  • 6.2.2. Pharmaceutical Grade
  • 6.2.3. Feed Grade
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Pharmaceutical Industry
  • 6.3.2. Food & Nutraceuticals Industry
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Vitamin B12 Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Cyanocobalamin
  • 7.1.2. Methylcobalamin
  • 7.1.3. Adenosylcobalamin
  • 7.1.4. Hydroxocobalamin
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Food Grade
  • 7.2.2. Pharmaceutical Grade
  • 7.2.3. Feed Grade
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Pharmaceutical Industry
  • 7.3.2. Food & Nutraceuticals Industry
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. Spain
  • 7.4.4. U.K.
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Vitamin B12 Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Cyanocobalamin
  • 8.1.2. Methylcobalamin
  • 8.1.3. Adenosylcobalamin
  • 8.1.4. Hydroxocobalamin
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Food Grade
  • 8.2.2. Pharmaceutical Grade
  • 8.2.3. Feed Grade
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Pharmaceutical Industry
  • 8.3.2. Food & Nutraceuticals Industry
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Vitamin B12 Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Cyanocobalamin
  • 9.1.2. Methylcobalamin
  • 9.1.3. Adenosylcobalamin
  • 9.1.4. Hydroxocobalamin
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Food Grade
  • 9.2.2. Pharmaceutical Grade
  • 9.2.3. Feed Grade
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Pharmaceutical Industry
  • 9.3.2. Food & Nutraceuticals Industry
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. EUROAPI
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. CSPC Pharmaceutical Group Co., Ltd.
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Ningxia Kingvit Pharmaceutical
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Pharmavit
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. NCPC INTERNATIONAL CORP.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)